These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 37791342)

  • 1. Microbial ecology between
    Kamiya S
    Biosci Microbiota Food Health; 2023; 42(4):229-235. PubMed ID: 37791342
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of the gut microbiome in colonization resistance and recurrent
    Seekatz AM; Safdar N; Khanna S
    Therap Adv Gastroenterol; 2022; 15():17562848221134396. PubMed ID: 36425405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection Prevention.
    Lavoie T; Appaneal HJ; LaPlante KL
    Clin Infect Dis; 2023 Dec; 77(Suppl 6):S447-S454. PubMed ID: 38051964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiota restoration therapies for recurrent
    DuPont HL; DuPont AW; Tillotson GS
    Therap Adv Gastroenterol; 2024; 17():17562848241253089. PubMed ID: 38800353
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Spigaglia P
    Pathogens; 2024 Jul; 13(8):. PubMed ID: 39204246
    [No Abstract]   [Full Text] [Related]  

  • 6. Gut microbiota changes associated with
    Gonzales-Luna AJ; Carlson TJ; Garey KW
    Gut Microbes; 2023; 15(1):2223345. PubMed ID: 37318134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
    Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
    Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The microbial metabolite urolithin A reduces
    Ghosh S; Erickson D; Chua MJ; Collins J; Jala VR
    mSystems; 2024 Feb; 9(2):e0125523. PubMed ID: 38193707
    [No Abstract]   [Full Text] [Related]  

  • 9. Gut microbiota in burned patients with Clostridioides difficile infection.
    Shoaei P; Shojaei H; Siadat SD; Moshiri A; Vakili B; Yadegari S; Ataei B; Khorvash F
    Burns; 2022 Aug; 48(5):1120-1129. PubMed ID: 34924229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SER-109 (VOWST
    Blair HA
    Drugs; 2024 Mar; 84(3):329-336. PubMed ID: 38441806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against
    Murphy CK; O'Donnell MM; Hegarty JW; Schulz S; Hill C; Ross RP; Rea MC; Farquhar R; Chesnel L
    World J Gastrointest Pathophysiol; 2023 Aug; 14(4):71-85. PubMed ID: 37727283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2'-Fucosyllactose inhibits proliferation of
    Wiese M; Schuren FHJ; Smits WK; Kuijper EJ; Ouwens A; Heerikhuisen M; Vigsnaes L; van den Broek TJ; de Boer P; Montijn RC; van der Vossen JMBM
    Front Cell Infect Microbiol; 2022; 12():991150. PubMed ID: 36389156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Butyrate Differentiates Permissiveness to Clostridioides difficile Infection and Influences Growth of Diverse C. difficile Isolates.
    Pensinger DA; Fisher AT; Dobrila HA; Van Treuren W; Gardner JO; Higginbottom SK; Carter MM; Schumann B; Bertozzi CR; Anikst V; Martin C; Robilotti EV; Chow JM; Buck RH; Tompkins LS; Sonnenburg JL; Hryckowian AJ
    Infect Immun; 2023 Feb; 91(2):e0057022. PubMed ID: 36692308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frontiers in antibiotic alternatives for
    Phanchana M; Harnvoravongchai P; Wongkuna S; Phetruen T; Phothichaisri W; Panturat S; Pipatthana M; Charoensutthivarakul S; Chankhamhaengdecha S; Janvilisri T
    World J Gastroenterol; 2021 Nov; 27(42):7210-7232. PubMed ID: 34876784
    [No Abstract]   [Full Text] [Related]  

  • 15. Influence of Binary Toxin Gene Detection and Decreased Susceptibility to Antibiotics among Clostridioides difficile Strains on Disease Severity: a Single-Center Study.
    Costa DVS; Pham NVS; Hays RA; Bolick DT; Goldbeck SM; Poulter MD; Hoang SC; Shin JH; Wu M; Warren CA
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0048922. PubMed ID: 35861541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational Design of Live Biotherapeutic Products for the Prevention of Clostridioides difficile Infection.
    Ke S; Gálvez JAV; Sun Z; Cao Y; Pollock NR; Chen X; Kelly CP; Liu YY
    J Infect Dis; 2024 Sep; ():. PubMed ID: 39316685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Bacterial and Fungal Dynamics following Oral Lyophilized Fecal Microbiota Transplantation in Clostridioides difficile Infection.
    Haifer C; Paramsothy S; Borody TJ; Clancy A; Leong RW; Kaakoush NO
    mSystems; 2021 Feb; 6(1):. PubMed ID: 33531405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diluted Fecal Community Transplant Restores Clostridioides difficile Colonization Resistance to Antibiotic-Perturbed Murine Communities.
    Lesniak NA; Tomkovich S; Henry A; Taylor A; Colovas J; Bishop L; McBride K; Schloss PD
    mBio; 2022 Aug; 13(4):e0136422. PubMed ID: 35913161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bile acids impact the microbiota, host, and
    McMillan AS; Theriot CM
    Gut Microbes; 2024; 16(1):2393766. PubMed ID: 39224076
    [No Abstract]   [Full Text] [Related]  

  • 20. Clostridioides
    Gawey BJ; Khanna S
    Gastroenterol Hepatol (N Y); 2023 Jun; 19(6):319-328. PubMed ID: 37706187
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.